Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7089480 | 1.00 | BCHE (0.60) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL31335199 | 0.88 | ALDH1A1 (0.57) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL11100850 | 0.88 | BCHE (0.54) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL4403903 | 0.88 | ALDH1A1 (0.57) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL4154642 | 0.86 | MEN1 (0.56) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL893963 | 0.86 | BCHE (0.63) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL11637705 | 0.86 | BCHE (0.60) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL11638716 | 0.85 | BCHE (0.51) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL7689676 | 0.85 | BCHE (0.51) | BCHEMEN1KMT2ATDP1ANPEP | |
| SCHEMBL7160696 | 0.85 | BCHE (0.51) | BCHEMEN1KMT2ATDP1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158152-A1 | Protease inhibitors and their pharmaceutical uses | CRUZ-FIOCRUZ, FUNDACAO OSWALDO (BR) | 2003-08-21 | — | — | US | claimed |
| US-20030158152-A1 | Protease inhibitors and their pharmaceutical uses | CRUZ-FIOCRUZ, FUNDACAO OSWALDO (BR) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158152-A1 | Protease inhibitors and their pharmaceutical uses | PEPD, DNPEP, PREP | BCHE 208/4885MEN1 1822/4885KMT2A 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.